Cwm LLC Purchases 3,213 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Cwm LLC increased its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 120.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 5,891 shares of the company’s stock after buying an additional 3,213 shares during the period. Cwm LLC’s holdings in Mineralys Therapeutics were worth $51,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of MLYS. Braidwell LP grew its position in shares of Mineralys Therapeutics by 267.8% in the third quarter. Braidwell LP now owns 2,023,900 shares of the company’s stock valued at $19,247,000 after purchasing an additional 1,473,600 shares during the last quarter. CHI Advisors LLC acquired a new stake in Mineralys Therapeutics in the 3rd quarter valued at approximately $5,405,000. FMR LLC lifted its holdings in shares of Mineralys Therapeutics by 62.6% during the third quarter. FMR LLC now owns 1,188,653 shares of the company’s stock worth $11,304,000 after buying an additional 457,815 shares during the last quarter. Laurion Capital Management LP boosted its position in shares of Mineralys Therapeutics by 42.6% in the third quarter. Laurion Capital Management LP now owns 969,978 shares of the company’s stock valued at $9,224,000 after acquiring an additional 289,847 shares during the period. Finally, Sectoral Asset Management Inc. grew its stake in shares of Mineralys Therapeutics by 36.8% in the third quarter. Sectoral Asset Management Inc. now owns 840,759 shares of the company’s stock worth $7,996,000 after acquiring an additional 226,046 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

Insider Activity

In related news, major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, February 12th. The shares were acquired at an average price of $13.50 per share, for a total transaction of $7,499,992.50. Following the transaction, the insider now directly owns 5,074,916 shares in the company, valued at $68,511,366. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 33.24% of the stock is currently owned by corporate insiders.

Mineralys Therapeutics Trading Down 2.6 %

NASDAQ MLYS opened at $14.27 on Friday. Mineralys Therapeutics, Inc. has a 1-year low of $5.85 and a 1-year high of $17.70. The company has a 50 day moving average of $12.92 and a 200-day moving average of $10.66. The firm has a market cap of $708.23 million, a price-to-earnings ratio of -7.14 and a beta of 2.05.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.61) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.24. On average, analysts forecast that Mineralys Therapeutics, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MLYS has been the subject of several analyst reports. Lifesci Capital restated an “outperform” rating on shares of Mineralys Therapeutics in a research report on Tuesday, March 26th. The Goldman Sachs Group began coverage on shares of Mineralys Therapeutics in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $30.00 target price on the stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.